BRIEF-Alnylam Pharma Announces New Positive Interim Phase 1 Study Results for Fitusiran By: Reuters: Company News July 25, 2016 at 13:55 PM EDT * Company updates guidance for phase 3, and now plans to start studies in early 2017 Read More >> Related Stocks: Alnylam Pharmaceuticals